New hep C treatment option greenlighted

The TGA has registered a new hepatitis C antiviral therapy, with a PBS listing expected by the end of the year.

Like previously approved antivirals, Zepatier can be used to treat patients with the genotype 1 virus, but it’s also the first interferon-free therapy to be approved for genotype 4.

The new antiviral combines the protease inhibitor grazoprevir with the NS5A inhibitor elbasvir into a once-daily